Bluejay Diagnostics, Inc. - 8-K Filing

Bluejay Diagnostics reports Q3 2026 results, completes SYMON-II clinical enrollment, and targets FDA 510(k) submission in H1 2027 (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)

SEC EDGAR ·

Tickers: $BJDX

Read the full article at SEC EDGAR

More Regulatory news